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Article
Renal transplantation has been associated with excellent patient and graft survival outcomes in HIV positive 
patients [1-3]. However, the incidence of acute allograft rejection (AR) remains high [4], with 31-48% of patients 
experiencing an episode of AR in the first year [1, 5]. The use of tacrolimus, a more potent calcineurin inhibitor 
than ciclosporin, has been associated with a reduced risk of AR [1, 6]. It is possible that more potent induction 
therapy may further reduce the risk of early AR. Alemtuzumab is a humanized monoclonal antibody targeted at 
CD52, a cell surface antigen present on both B and T lymphocytes, which has a profound lymphocyte depleting 
effect. While Alemtuzumab, which is not currently licensed for transplantation in the UK, has been associated 
with lower rates of AR in HIV negative renal transplant recipients [7], experience in HIV positive renal transplant 
recipients is limited.  
Case 1 
A 57 year old Black Caribbean man underwent deceased-donor renal transplantation in 2013 for end-stage 
diabetic nephropathy (HLA mismatch: 3). At the time of transplantation, his antiretroviral therapy consisted of 
abacavir, lamivudine and raltegravir; he was cytomegalovirus (CMV) IgG positive, his CD4 T-cell count was 394 
cells/mm3, HIV RNA undetectable, and he had no history of opportunistic infections or malignancy. He received 
preconditioning therapy with alemtuzumab (35mg) followed by tacrolimus (titrated up to and maintained 
around 16 mg/day in the first year, aiming for trough concentrations of 5-8 ng/ml), with glucocorticoid cover for 
one week, valganciclovir prophylaxis for three months, co-trimoxazole prophylaxis for six months, and isoniazid. 
Case 2 
A 47 year old Black African man also underwent deceased donor renal transplantation in 2013 for end-stage 
kidney disease secondary to HIV-associated nephropathy (HLA mismatch: 3). At the time of transplantation, his 
antiretroviral therapy also consisted of abacavir, lamivudine and raltegravir; he was CMV IgG positive, his CD4 T-
cell count was 328 cells/mm3, HIV RNA undetectable, and he had no history of opportunistic infections or 
malignancy. He received alemtuzumab (30mg) followed by tacrolimus (titrated up to 16 mg/day in the first two 
months), with glucocorticoids for one week and the same prophylactic regimen as Case 1. 
Both patients experienced profound CD4 and CD8 T-cell depletion (<10 and <20 cells/mm3) in the first 3 months 
post-transplantation with subsequent recovery. In both cases, HIV and CMV viral loads remained undetectable 
throughout, and no AR, opportunistic infection or malignancy occurred. Case 1 had prolonged, low level EBV 
viraemia (21,000 copies/mL) without evidence of post-transplant lymphoproliferative disease, and case 2 
experienced a gradual decline in estimated glomerular filtration rate (eGFR, from 53 to 32 ml/min/1.73m3) at 2 
months; a renal biopsy revealed acute tubular necrosis. Calcineurin inhibitor toxicity was suspected and graft 
function improved when the dose of tacrolimus was reduced to 8-10mg/day. Both patients had well-functioning 
grafts at their most recent visit (eGFR 75 and 50 ml/min/1.73m3). 
Here we report two cases of renal transplantation in HIV positive patients on an integrase inhibitor containing 
antiretroviral regimen who received induction therapy with alemtuzumab. Our experience concurs with that of 
Tan et al. who treated three HIV-positive recipients of live-donor renal allografts with alemtuzumab (30mg, plus 
short term glucocorticoids) and tacrolimus maintenance immunosuppression, reporting no acute rejection, 
opportunistic infections or malignancy during median follow up of 39 months [8].  A further 29 HIV positive 
patients received a renal transplant with alemtuzumab induction therapy up to 2011 in the United States 
although complications such as opportunistic infections and malignancy were was not reported [4]. Our data 
suggest that the clinical utility of alemtuzumab in HIV positive kidney transplant recipients warrants further 
investigation, especially in those at high immunological risk of AR or when glucocorticoid-sparing, low-intensity 
calcineurin inhibitor exposure is desirable. Such studies, however, should evaluate the long term safety of 
severe T cell depletion in this population.  
 References 
1. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of Kidney Transplantation in 
HIV-Infected Recipients. N Engl J Med 2010,363:2004-2014. 
2. Gathogo EN, Hamzah L, Hilton R, Marshall N, Ashley C, Harber M, et al. Kidney transplantation in HIV-
positive adults: the UK experience. Int J STD AIDS 2014,25:57-66. 
3. Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, et al. Survival in HIV-positive 
transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS 
2016,30:435-444. 
4. Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, et al. Immunosuppression regimen 
and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation 
2014,97:446-450. 
5. Gathogo E, Jose S, Jones R, Levy JB, Mackie NE, Booth J, et al. End-Stage Kidney Disease and Kidney 
Transplantation in HIV-Positive Patients: An Observational Cohort Study. J Acquir Immune Defic Syndr 
2014,67:177-180. 
6. Gathogo E, Harber M, Bhagani S, Levy J, Jones R, Hilton R, et al. Impact of Tacrolimus Compared With 
Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive 
Kidney Transplant Recipients. Transplantation 2016,100:871-878. 
7. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction 
in renal transplantation. N Engl J Med 2011,364:1909-1919. 
8. Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, et al. Living-related donor renal 
transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus 
monotherapy: a single center preliminary experience. Transplantation 2004,78:1683-1688. 
 
